Now if we consider amyloid beta therapies: we have treatments that target amyloid beta with varying degrees of success but at least some show definite reductions in amyloid beta plaques. To the best of my knowledge that has not shown to improve outcomes in Alzheimer's patients to any meaningful degree.
replyThis is false. They slow down disease progression by about 30%, as measured by cognitive outcomes. This is discussed in the article.